Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease

Area of Science:

• Cardiovascular Medicine
• Endocrinology
• Pharmacology

Background:

• Post-menopausal women with coronary artery disease often have hypercholesterolemia.
• Cell adhesion molecules play a role in the inflammatory response and atherosclerosis.
• Lipoprotein(a) is an independent risk factor for cardiovascular disease.

Purpose of the Study:

• To evaluate the effects of simvastatin, hormone replacement therapy (HRT), and their combination on plasma lipids and soluble cell adhesion molecules.
• To assess these effects in hypercholesterolemic post-menopausal women with established coronary artery disease.

Main Methods:

• A randomized, crossover, placebo-controlled study involving 16 post-menopausal women.
• Treatments included simvastatin (20 mg/day), HRT (conjugated oestrogen/medroxyprogesterone acetate), and their combination, each for 8 weeks with 4-week washout periods.
• Plasma lipids and circulating cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) were measured.

Main Results:

• All active treatments significantly reduced total and LDL cholesterol compared to placebo.
• HRT, alone and combined with simvastatin, significantly decreased lipoprotein(a) levels.
• HRT and combination therapy significantly reduced intercellular adhesion molecule-1 (ICAM-1) levels, while simvastatin did not.
• Simvastatin was more effective than HRT in lowering LDL cholesterol but did not affect ICAM-1.

Conclusions:

• Hormone replacement therapy may mitigate the inflammatory response in atherosclerosis by modulating endothelial cell adhesion molecule expression.
• The reduction in cell adhesion molecules by HRT may be associated with a decrease in lipoprotein(a).
• Simvastatin effectively lowers cholesterol but does not appear to influence key inflammatory markers like ICAM-1 in this population.